While some GLP-1s are approved for patients age 12 and older, only a few telehealth companies will prescribe them to children.

Nov. 6, 2024 – The FDA has updated the labels for all GLP-1 weight loss drugs with a warning about pulmonary aspiration ...

On November 5, the US Food and Drug Administration (FDA) updated the labels for all glucagon-like peptide 1 receptor agonists (GLP-1 RA) with a warning about pulmonary aspiration during general ...

News Do Certain Diabetes Drugs Increase the Risk of Acute Kidney Injury in Patients Taking Anti-Cancer Therapies? Glucagon-like peptide-1-receptor agonists (GLP-1RA) are medicatio ...

Medically reviewed by Lindsay Cook, PharmD Ozempic is the brand name of semaglutide, a glucagon-like peptide-1 (GLP-1) ...

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) can decrease the risk for developing early-onset colorectal cancer ...

Only 13 states currently allow Medicaid to cover treatment of obesity using glucagon-like peptide-1 agonist (GLP-1) medications, researchers said.

Nearly 16% of American adults -- that's close to 1 in 6 -- now has diabetes, according to the latest data from the U.S.

Kentucky, Alaska and Alabama are the three states where weight loss drugs are most used, and Hawaii, Arizona and Colorado sit ...

In a multisociety clinical practice guidance document, published online Oct. 29 in Surgery for Obesity and Related Diseases, ...

Results from a retrospective cohort study show lower all-cause mortality and fewer hospitalizations and intestinal ...

especially for non–glucagon-like peptide 1 (GLP-1) receptor agonists. One third reported that they didn’t prescribe AOMs, and ...